ANAHEIM, Calif.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO™ (ivacaftor, VX-770), a medicine in development that targets the defective protein that causes cystic fibrosis (CF). ENVISION (n=52) was designed to evaluate children with CF ages 6 to 11 years who had at least one copy of the G551D mutation. Approximately 1,200 people in the United States and 1,000 people in Europe with CF are estimated to have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These results, as well as the first data from PERSIST, the long-term follow-up study of adolescents and adults treated in the Phase 3 STRIVE study, are being presented at the 25th Annual North American CF Conference (NACFC), November 3-5, 2011 in Anaheim, Calif.
